文献速递头颈部肿瘤放疗

HPV相关口咽鳞癌经口机器人术后辅助放疗减量减野的2期试验长期结果

Long-Term Results of a Phase 2 Clinical Trial of Radiation Volume and Dose Deintensification Following Transoral Robotic Surgery and Neck Dissection for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-04-16

该2期试验纳入149例接受经口机器人手术及颈清扫的HPV相关口咽鳞癌患者,术后辅助放疗采用减量减野策略。中位随访48个月,5年局部区域控制率为98.0%,无局部复发,2例区域复发均成功挽救,10例(6.7%)出现远处转移,3例(2.0%)死于疾病。术后可检测HPV ctDNA与后续转移相关。

要点

  • 5年局部区域控制率达98.0%,无局部复发,仅2例区域复发且均成功挽救。
  • 减量减野辅助放疗后24个月吞咽困难与口干中位评分均为2分,工作干扰为0分。
  • 术后可检测HPV ctDNA与后续远处转移相关,但与局部区域控制无关。

核心结论

  • 在经选择的HPV相关口咽鳞癌患者中,术后减量减野辅助放疗维持了高局部区域控制率并具有良好毒性特征。

研究设计与样本

  • 2期临床试验,2018年10月至2022年6月入组150例,1例退出,149例按方案治疗。
  • eligible患者为pT0-pT3 pN0-pN1 HPV相关口咽鳞癌(AJCC第8版),接受经口机器人手术及颈清扫。
  • 辅助放疗25次/5周,选择性省略原发切除床,对侧颈部靶区缩减至镜像同侧病理阳性淋巴结区域。
  • 放疗剂量:需治疗的原发切除床及同侧病理阳性淋巴结区50 Gy,其他高危同侧淋巴结区及对侧颈部45 Gy。
  • 切缘阳性或结外延伸者接受同步化疗,结外延伸≤1 mm时可选择省略。

主要发现

  • 中位随访48个月(IQR 38-59个月),无局部复发,2例区域复发,均成功挽救。
  • 估计5年局部区域控制率为98.0%(95% CI 95.3%-100%)。
  • 10例(6.7%)出现远处转移,3例(2.0%)死于疾病。
  • 放疗后24个月,MD Anderson头颈症状量表评分中位数为吞咽困难2分、口干2分、工作干扰0分。
  • 79例有血样患者中,术后可检测HPV ctDNA与后续转移性疾病相关,但与局部区域控制无关。

关键数值与推荐

  • 选择性省略原发切除床的条件为pT1-T2肿瘤、切缘阴性且无淋巴血管侵犯或神经周围侵犯。
  • 对侧颈部靶区缩减为镜像同侧病理阳性淋巴结区域。
  • 原发切除床及同侧病理阳性淋巴结区剂量50 Gy,其他高危同侧淋巴结区及对侧颈部45 Gy。
  • 同步化疗用于切缘阳性及结外延伸,结外延伸≤1 mm时可选择省略。

临床怎么用

  • 对经选择的HPV相关口咽鳞癌患者,经口机器人术后可采用减量减野辅助放疗以维持高局部区域控制并降低毒性。
  • 术后可检测HPV ctDNA提示远处转移风险,但与局部区域控制无关。

局限性

  • 为2期单臂试验,样本量149例,随访中位48个月。
  • ctDNA分析仅79例有可用血样。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We conducted a phase 2 clinical trial reducing both dose and volume of adjuvant radiation in patients with human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). We also examined whether postoperative circulating tumor DNA (ctDNA) was prognostic for outcomes. METHODS AND MATERIALS: Eligible patients had pT0 to pT3 pN0 to pN1 HPV-associated OPSCC (American Joint Committee on Cancer 8th edition) treated with primary transoral robotic surgery and neck dissection. Adjuvant radiation therapy (RT) was delivered in 25 fractions over 5 weeks. We reduced RT volumes in 2 ways: the primary oropharyngeal resection bed was omitted in select patients (pT1-T2 tumors with negative margins and no lymphovascular invasion or perineural invasion), and the contralateral neck targets were reduced to mirror the pathologically involved ipsilateral nodal levels. We also reduced RT doses: 50 Gy was given to primary resection beds requiring treatment and to ipsilateral neck levels with pathologically positive nodes; 45 Gy was delivered to other at-risk ipsilateral nodal regions and the contralateral neck. Concurrent chemotherapy was prescribed for positive margins and extranodal extension, although optionally omitted when extranodal extension was ≤1 mm. Baseline HPV ctDNA was collected after surgery and measured at 3 subsequent timepoints. RESULTS: We enrolled 150 patients between October 2018 and June 2022. One patient withdrew, leaving 149 patients treated per protocol. At a median follow-up of 48 months (IQR, 38-59 months), no patients developed local recurrence while 2 experienced regional recurrences. The estimated 5-year locoregional control (LRC) rate was 98.0% (95% CI, 95.3%-100%). Both regional recurrences were successfully salvaged. Ten patients (6.7%) developed distant metastases, and 3 (2.0%) died of disease. At 24 months post-RT, the median MD Anderson Symptom Inventory for head and neck cancer scores were dysphagia-2, xerostomia-2, and interference with work-0. For 79 patients with available blood samples, detectable postoperative HPV ctDNA was associated with subsequent metastatic disease but not LRC. CONCLUSIONS: Now with mature follow-up, our adjuvant RT strategy with reduced doses and volumes maintained high LRC with favorable toxicity in selected patients with HPV-associated OPSCC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Lukens JN, Riina MD, Weinstein G, et al. Long-Term Results of a Phase 2 Clinical Trial of Radiation Volume and Dose Deintensification Following Transoral Robotic Surgery and Neck Dissection for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2026. PMID: 41999781. doi:10.1016/j.ijrobp.2026.04.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。